Figure 3
4-MDDT does not recapitulate the actions of MPA against AML cell lines. HL-60, K562 and KG1a cells were treated for 7 days with either solvent control, 50 μ M 4-MDDT or 5 μ M MPA, alone or in combination with 0.5 mM BEZ. (A) Cumulative cell counts for HL60, K562 and KG1a after 7 days treatment. Data shown is mean of a minimum of N=3 experiments±s.e.m. (B and D) HL60 differentiation was assessed at day 7 by staining for CD11b and flow cytometry following treatment with either solvent control, 50 μ M 4-MDDT or 5 μ M MPA with or without 0.5 mM BEZ or 10 nM ATRA. Data shown is mean of a minimum of N=3 experiments±s.e.m. (C) Cytospins of HL60 cells treated for 7 days as described above were stained with Jenner–Giemsa to demonstrate changes in cell morphology. (E) Intracellular AKR1C3 11β-prostaglandin reductase activity in KG1a cells was assessed in the presence of a dose titration of 4-MDDT or 5 μ M MPA using 3H-PGD2 and thin layer chromatography. Data shown is mean of N=4 experiments±s.e.m. *P<0.01.
